BioPharmSignal logoBioPharmSignal

Biotech News

Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist

Biomea Fusion (BMEA)Biomea FusionConference / presentation

Company to host conference call and webcast on October 13, 2026, at 4:30 p.m. ET (1:30 p.m. PT) SAN CARLOS, Calif., Oct. 12, 2026 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea” or the “Company”) (Nasdaq: BMEA), a clinical-stage biopharmaceutical company, today announced that it will report

Related news

BMEABiomea Fusion2026-10-13 20:08 EST

Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist

ZNTLZentalis2026-10-18 22:05 EST

Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract

ELVNEnliven Therapeutics2026-08-31 22:05 EST

Enliven Therapeutics Announces Oral and Poster Presentations at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting

PRLDPrelude Therapeutics2026-10-16 20:01 EST

Prelude Therapeutics to Participate in the Chardan Healthcare Conference

CHRSCoherus BioSciences, Inc.2026-10-14 20:30 EST

Coherus Oncology to Host Webcast to Disclose Interim Tagmokitug Clinical Data on October 28, 2026

STROSutro Biopharma2026-10-12 12:00 EST

Sutro Biopharma Announces Participation at the 17th Annual World ADC Conference

BMEABiomea Fusion2026-09-23 11:04 EST

Biomea Fusion Announces Termination of Proposed Public Offering of Securities

LYELLyell Immunopharma2026-09-14 11:00 EST

Lyell Immunopharma To Participate in the Baird 2026 Global Healthcare Conference

PRLDPrelude Therapeutics2026-09-11 11:01 EST

Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

MGNXMacroGenics2026-09-09 20:05 EST

MacroGenics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

View all latest news

Biomea Fusion

Metabolic Disease Company Biomea Fusion develops small molecules intended to restore metabolic function in diabetes and obesity. Icovamenib Icovamenib is a covalent menin inhibitor being evaluated for potential restoration of insulin-producing beta-cell function in type 1 and type 2 diabetes. COVALENT Program COVALENT-211 and...

Recent company news

BMEABiomea Fusion2026-10-13 20:08 EST

Biomea Fusion Announces Phase 1 Results for BMF-650, its Investigational Next-Generation Oral Small Molecule GLP-1 Receptor Agonist

BMEABiomea Fusion2026-10-12 20:30 EST

Biomea Fusion to Announce Phase I Results for BMF-650, Its Next-Generation Oral Small-Molecule GLP-1 Receptor Agonist

BMEABiomea Fusion2026-09-23 11:04 EST

Biomea Fusion Announces Termination of Proposed Public Offering of Securities

BMEABiomea Fusion2026-09-22 20:05 EST

Biomea Fusion Announces Proposed Public Offering of Securities

BMEABiomea Fusion2026-09-03 12:00 EST

Biomea Fusion to Participate in Upcoming Investor Conferences

Stock data

Close
0.69 USD
Market cap
99.05M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States